HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $32
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $28 to $32.
HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $28 to $32.